▶ 調査レポート

世界のフィブラート医薬品市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Fibrate Drugs Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界のフィブラート医薬品市場規模・現状・予測(2021年-2027年) / Global Fibrate Drugs Market Size, Status and Forecast 2021-2027 / QFJ1-4223資料のイメージです。• レポートコード:QFJ1-4223
• 出版社/出版日:QYResearch / 2021年6月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、107ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、フィブラート医薬品の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(ロフィブレート、フェノフィブラート、フェノフィブラート、ゲムフィブロジル)、用途別市場規模(病院薬局、小売薬局、オンライン薬局)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・フィブラート医薬品の市場動向
・企業の競争状況、市場シェア
・フィブラート医薬品の種類別市場規模と予測2016-2027(ロフィブレート、フェノフィブラート、フェノフィブラート、ゲムフィブロジル)
・フィブラート医薬品の用途別市場規模と予測2016-2027(病院薬局、小売薬局、オンライン薬局)
・フィブラート医薬品の北米市場規模2016-2027(アメリカ、カナダ)
・フィブラート医薬品の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・フィブラート医薬品のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・フィブラート医薬品の中南米市場規模2016-2027(メキシコ、ブラジル)
・フィブラート医薬品の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Teva Pharmaceutical Industries、Pfizer, Inc.、Mylan N.V.、Sanofi SA、Novartis AG、GlaxoSmithKline plc、Sun Pharmaceutical Industries, Inc.、Macleods Pharmaceuticals Limited、Aurobindo Pharma、Abbott)
・結論

Market Analysis and Insights: Global Fibrate Drugs Market
The global Fibrate Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Fibrate Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Fibrate Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Fibrate Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Fibrate Drugs market.

Global Fibrate Drugs Scope and Market Size
Fibrate Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Fibrate Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Lofibrate
Fenofibrates
Fenofibric Acids
Gemfibrozil

Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Teva Pharmaceutical Industries
Pfizer, Inc.
Mylan N.V.
Sanofi SA
Novartis AG
GlaxoSmithKline plc
Sun Pharmaceutical Industries, Inc.
Macleods Pharmaceuticals Limited
Aurobindo Pharma
Abbott

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Fibrate Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lofibrate
1.2.3 Fenofibrates
1.2.4 Fenofibric Acids
1.2.5 Gemfibrozil
1.3 Market by Application
1.3.1 Global Fibrate Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Fibrate Drugs Market Perspective (2016-2027)
2.2 Fibrate Drugs Growth Trends by Regions
2.2.1 Fibrate Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Fibrate Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Fibrate Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Fibrate Drugs Industry Dynamic
2.3.1 Fibrate Drugs Market Trends
2.3.2 Fibrate Drugs Market Drivers
2.3.3 Fibrate Drugs Market Challenges
2.3.4 Fibrate Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Fibrate Drugs Players by Revenue
3.1.1 Global Top Fibrate Drugs Players by Revenue (2016-2021)
3.1.2 Global Fibrate Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Fibrate Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Fibrate Drugs Revenue
3.4 Global Fibrate Drugs Market Concentration Ratio
3.4.1 Global Fibrate Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Fibrate Drugs Revenue in 2020
3.5 Fibrate Drugs Key Players Head office and Area Served
3.6 Key Players Fibrate Drugs Product Solution and Service
3.7 Date of Enter into Fibrate Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Fibrate Drugs Breakdown Data by Type
4.1 Global Fibrate Drugs Historic Market Size by Type (2016-2021)
4.2 Global Fibrate Drugs Forecasted Market Size by Type (2022-2027)

5 Fibrate Drugs Breakdown Data by Application
5.1 Global Fibrate Drugs Historic Market Size by Application (2016-2021)
5.2 Global Fibrate Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Fibrate Drugs Market Size (2016-2027)
6.2 North America Fibrate Drugs Market Size by Type
6.2.1 North America Fibrate Drugs Market Size by Type (2016-2021)
6.2.2 North America Fibrate Drugs Market Size by Type (2022-2027)
6.2.3 North America Fibrate Drugs Market Size by Type (2016-2027)
6.3 North America Fibrate Drugs Market Size by Application
6.3.1 North America Fibrate Drugs Market Size by Application (2016-2021)
6.3.2 North America Fibrate Drugs Market Size by Application (2022-2027)
6.3.3 North America Fibrate Drugs Market Size by Application (2016-2027)
6.4 North America Fibrate Drugs Market Size by Country
6.4.1 North America Fibrate Drugs Market Size by Country (2016-2021)
6.4.2 North America Fibrate Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Fibrate Drugs Market Size (2016-2027)
7.2 Europe Fibrate Drugs Market Size by Type
7.2.1 Europe Fibrate Drugs Market Size by Type (2016-2021)
7.2.2 Europe Fibrate Drugs Market Size by Type (2022-2027)
7.2.3 Europe Fibrate Drugs Market Size by Type (2016-2027)
7.3 Europe Fibrate Drugs Market Size by Application
7.3.1 Europe Fibrate Drugs Market Size by Application (2016-2021)
7.3.2 Europe Fibrate Drugs Market Size by Application (2022-2027)
7.3.3 Europe Fibrate Drugs Market Size by Application (2016-2027)
7.4 Europe Fibrate Drugs Market Size by Country
7.4.1 Europe Fibrate Drugs Market Size by Country (2016-2021)
7.4.2 Europe Fibrate Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Fibrate Drugs Market Size (2016-2027)
8.2 Asia-Pacific Fibrate Drugs Market Size by Type
8.2.1 Asia-Pacific Fibrate Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Fibrate Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Fibrate Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Fibrate Drugs Market Size by Application
8.3.1 Asia-Pacific Fibrate Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Fibrate Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Fibrate Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Fibrate Drugs Market Size by Region
8.4.1 Asia-Pacific Fibrate Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Fibrate Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Fibrate Drugs Market Size (2016-2027)
9.2 Latin America Fibrate Drugs Market Size by Type
9.2.1 Latin America Fibrate Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Fibrate Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Fibrate Drugs Market Size by Type (2016-2027)
9.3 Latin America Fibrate Drugs Market Size by Application
9.3.1 Latin America Fibrate Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Fibrate Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Fibrate Drugs Market Size by Application (2016-2027)
9.4 Latin America Fibrate Drugs Market Size by Country
9.4.1 Latin America Fibrate Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Fibrate Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Fibrate Drugs Market Size (2016-2027)
10.2 Middle East & Africa Fibrate Drugs Market Size by Type
10.2.1 Middle East & Africa Fibrate Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Fibrate Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Fibrate Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Fibrate Drugs Market Size by Application
10.3.1 Middle East & Africa Fibrate Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Fibrate Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Fibrate Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Fibrate Drugs Market Size by Country
10.4.1 Middle East & Africa Fibrate Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Fibrate Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Teva Pharmaceutical Industries
11.1.1 Teva Pharmaceutical Industries Company Details
11.1.2 Teva Pharmaceutical Industries Business Overview
11.1.3 Teva Pharmaceutical Industries Fibrate Drugs Introduction
11.1.4 Teva Pharmaceutical Industries Revenue in Fibrate Drugs Business (2016-2021)
11.1.5 Teva Pharmaceutical Industries Recent Development
11.2 Pfizer, Inc.
11.2.1 Pfizer, Inc. Company Details
11.2.2 Pfizer, Inc. Business Overview
11.2.3 Pfizer, Inc. Fibrate Drugs Introduction
11.2.4 Pfizer, Inc. Revenue in Fibrate Drugs Business (2016-2021)
11.2.5 Pfizer, Inc. Recent Development
11.3 Mylan N.V.
11.3.1 Mylan N.V. Company Details
11.3.2 Mylan N.V. Business Overview
11.3.3 Mylan N.V. Fibrate Drugs Introduction
11.3.4 Mylan N.V. Revenue in Fibrate Drugs Business (2016-2021)
11.3.5 Mylan N.V. Recent Development
11.4 Sanofi SA
11.4.1 Sanofi SA Company Details
11.4.2 Sanofi SA Business Overview
11.4.3 Sanofi SA Fibrate Drugs Introduction
11.4.4 Sanofi SA Revenue in Fibrate Drugs Business (2016-2021)
11.4.5 Sanofi SA Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Fibrate Drugs Introduction
11.5.4 Novartis AG Revenue in Fibrate Drugs Business (2016-2021)
11.5.5 Novartis AG Recent Development
11.6 GlaxoSmithKline plc
11.6.1 GlaxoSmithKline plc Company Details
11.6.2 GlaxoSmithKline plc Business Overview
11.6.3 GlaxoSmithKline plc Fibrate Drugs Introduction
11.6.4 GlaxoSmithKline plc Revenue in Fibrate Drugs Business (2016-2021)
11.6.5 GlaxoSmithKline plc Recent Development
11.7 Sun Pharmaceutical Industries, Inc.
11.7.1 Sun Pharmaceutical Industries, Inc. Company Details
11.7.2 Sun Pharmaceutical Industries, Inc. Business Overview
11.7.3 Sun Pharmaceutical Industries, Inc. Fibrate Drugs Introduction
11.7.4 Sun Pharmaceutical Industries, Inc. Revenue in Fibrate Drugs Business (2016-2021)
11.7.5 Sun Pharmaceutical Industries, Inc. Recent Development
11.8 Macleods Pharmaceuticals Limited
11.8.1 Macleods Pharmaceuticals Limited Company Details
11.8.2 Macleods Pharmaceuticals Limited Business Overview
11.8.3 Macleods Pharmaceuticals Limited Fibrate Drugs Introduction
11.8.4 Macleods Pharmaceuticals Limited Revenue in Fibrate Drugs Business (2016-2021)
11.8.5 Macleods Pharmaceuticals Limited Recent Development
11.9 Aurobindo Pharma
11.9.1 Aurobindo Pharma Company Details
11.9.2 Aurobindo Pharma Business Overview
11.9.3 Aurobindo Pharma Fibrate Drugs Introduction
11.9.4 Aurobindo Pharma Revenue in Fibrate Drugs Business (2016-2021)
11.9.5 Aurobindo Pharma Recent Development
11.10 Abbott
11.10.1 Abbott Company Details
11.10.2 Abbott Business Overview
11.10.3 Abbott Fibrate Drugs Introduction
11.10.4 Abbott Revenue in Fibrate Drugs Business (2016-2021)
11.10.5 Abbott Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Fibrate Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Lofibrate
Table 3. Key Players of Fenofibrates
Table 4. Key Players of Fenofibric Acids
Table 5. Key Players of Gemfibrozil
Table 6. Global Fibrate Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Fibrate Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Fibrate Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Fibrate Drugs Market Share by Regions (2016-2021)
Table 10. Global Fibrate Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Fibrate Drugs Market Share by Regions (2022-2027)
Table 12. Fibrate Drugs Market Trends
Table 13. Fibrate Drugs Market Drivers
Table 14. Fibrate Drugs Market Challenges
Table 15. Fibrate Drugs Market Restraints
Table 16. Global Fibrate Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Fibrate Drugs Market Share by Players (2016-2021)
Table 18. Global Top Fibrate Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fibrate Drugs as of 2020)
Table 19. Ranking of Global Top Fibrate Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Fibrate Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Fibrate Drugs Product Solution and Service
Table 23. Date of Enter into Fibrate Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Fibrate Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Fibrate Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Fibrate Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Fibrate Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Fibrate Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Fibrate Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Fibrate Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Fibrate Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Fibrate Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Fibrate Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Fibrate Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Fibrate Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Fibrate Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Fibrate Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Fibrate Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Fibrate Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Fibrate Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Fibrate Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Fibrate Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Fibrate Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Fibrate Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Fibrate Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Fibrate Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Fibrate Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Fibrate Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Fibrate Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Fibrate Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Fibrate Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Fibrate Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Fibrate Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Fibrate Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Fibrate Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Fibrate Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Fibrate Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Fibrate Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Fibrate Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Fibrate Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Fibrate Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. Teva Pharmaceutical Industries Company Details
Table 64. Teva Pharmaceutical Industries Business Overview
Table 65. Teva Pharmaceutical Industries Fibrate Drugs Product
Table 66. Teva Pharmaceutical Industries Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 67. Teva Pharmaceutical Industries Recent Development
Table 68. Pfizer, Inc. Company Details
Table 69. Pfizer, Inc. Business Overview
Table 70. Pfizer, Inc. Fibrate Drugs Product
Table 71. Pfizer, Inc. Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 72. Pfizer, Inc. Recent Development
Table 73. Mylan N.V. Company Details
Table 74. Mylan N.V. Business Overview
Table 75. Mylan N.V. Fibrate Drugs Product
Table 76. Mylan N.V. Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 77. Mylan N.V. Recent Development
Table 78. Sanofi SA Company Details
Table 79. Sanofi SA Business Overview
Table 80. Sanofi SA Fibrate Drugs Product
Table 81. Sanofi SA Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 82. Sanofi SA Recent Development
Table 83. Novartis AG Company Details
Table 84. Novartis AG Business Overview
Table 85. Novartis AG Fibrate Drugs Product
Table 86. Novartis AG Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 87. Novartis AG Recent Development
Table 88. GlaxoSmithKline plc Company Details
Table 89. GlaxoSmithKline plc Business Overview
Table 90. GlaxoSmithKline plc Fibrate Drugs Product
Table 91. GlaxoSmithKline plc Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 92. GlaxoSmithKline plc Recent Development
Table 93. Sun Pharmaceutical Industries, Inc. Company Details
Table 94. Sun Pharmaceutical Industries, Inc. Business Overview
Table 95. Sun Pharmaceutical Industries, Inc. Fibrate Drugs Product
Table 96. Sun Pharmaceutical Industries, Inc. Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 97. Sun Pharmaceutical Industries, Inc. Recent Development
Table 98. Macleods Pharmaceuticals Limited Company Details
Table 99. Macleods Pharmaceuticals Limited Business Overview
Table 100. Macleods Pharmaceuticals Limited Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 101. Macleods Pharmaceuticals Limited Recent Development
Table 102. Aurobindo Pharma Company Details
Table 103. Aurobindo Pharma Business Overview
Table 104. Aurobindo Pharma Fibrate Drugs Product
Table 105. Aurobindo Pharma Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 106. Aurobindo Pharma Recent Development
Table 107. Abbott Company Details
Table 108. Abbott Business Overview
Table 109. Abbott Fibrate Drugs Product
Table 110. Abbott Revenue in Fibrate Drugs Business (2016-2021) & (US$ Million)
Table 111. Abbott Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Fibrate Drugs Market Share by Type: 2020 VS 2027
Figure 2. Lofibrate Features
Figure 3. Fenofibrates Features
Figure 4. Fenofibric Acids Features
Figure 5. Gemfibrozil Features
Figure 6. Global Fibrate Drugs Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Fibrate Drugs Report Years Considered
Figure 11. Global Fibrate Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Fibrate Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Fibrate Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Fibrate Drugs Market Share by Regions (2022-2027)
Figure 15. Global Fibrate Drugs Market Share by Players in 2020
Figure 16. Global Top Fibrate Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fibrate Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Fibrate Drugs Revenue in 2020
Figure 18. Global Fibrate Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Fibrate Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Fibrate Drugs Market Share by Type (2016-2027)
Figure 22. North America Fibrate Drugs Market Share by Application (2016-2027)
Figure 23. North America Fibrate Drugs Market Share by Country (2016-2027)
Figure 24. United States Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Fibrate Drugs Market Share by Type (2016-2027)
Figure 28. Europe Fibrate Drugs Market Share by Application (2016-2027)
Figure 29. Europe Fibrate Drugs Market Share by Country (2016-2027)
Figure 30. Germany Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Fibrate Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Fibrate Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Fibrate Drugs Market Share by Region (2016-2027)
Figure 40. China Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Fibrate Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Fibrate Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Fibrate Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Fibrate Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Fibrate Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Fibrate Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Fibrate Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Teva Pharmaceutical Industries Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 60. Pfizer, Inc. Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 61. Mylan N.V. Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 62. Sanofi SA Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 63. Novartis AG Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 64. GlaxoSmithKline plc Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 65. Sun Pharmaceutical Industries, Inc. Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 66. Macleods Pharmaceuticals Limited Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 67. Aurobindo Pharma Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 68. Abbott Revenue Growth Rate in Fibrate Drugs Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed